tetano
Editor, Senior Moderator
Hum Vaccin Immunother
. 2020 Dec 3;1-6.
doi: 10.1080/21645515.2020.1842683. Online ahead of print.
COVID-19 in the elderly people and advances in vaccination approaches
Kuldeep Dhama[SUP] 1 [/SUP], Shailesh Kumar Patel[SUP] 1 [/SUP], Senthilkumar Natesan[SUP] 2 [/SUP], Kranti Suresh Vora[SUP] 2 3 [/SUP], Mohd Iqbal Yatoo[SUP] 4 [/SUP], Ruchi Tiwari[SUP] 5 [/SUP], Shailendra K Saxena[SUP] 6 [/SUP], Karam Pal Singh[SUP] 1 [/SUP], Rajendra Singh[SUP] 1 [/SUP], Yashpal Singh Malik[SUP] 7 [/SUP]
Affiliations
Abstract
The rapid worldwide spread of the COVID-19 pandemic, caused by the newly emerged severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has resulted in tens of millions of infections and over one million deaths. SARS-CoV-2 infection affects all age groups; however, those over 60 years old are affected more severely. Moreover, pre-existing co-morbidities result in higher COVID-19-associated mortality in the geriatric population. This article highlights the associated risk factors of SARS-CoV-2 infection in older people and progress in developing COVID-19 vaccines, especially for efficient vaccination of the older population. There is also a summary of immunomodulatory and immunotherapeutic approaches to ameliorate the outcome of COVID-19 in older individuals.
Keywords: SARS-CoV-2; covid-19; elderly people; vaccine.
. 2020 Dec 3;1-6.
doi: 10.1080/21645515.2020.1842683. Online ahead of print.
COVID-19 in the elderly people and advances in vaccination approaches
Kuldeep Dhama[SUP] 1 [/SUP], Shailesh Kumar Patel[SUP] 1 [/SUP], Senthilkumar Natesan[SUP] 2 [/SUP], Kranti Suresh Vora[SUP] 2 3 [/SUP], Mohd Iqbal Yatoo[SUP] 4 [/SUP], Ruchi Tiwari[SUP] 5 [/SUP], Shailendra K Saxena[SUP] 6 [/SUP], Karam Pal Singh[SUP] 1 [/SUP], Rajendra Singh[SUP] 1 [/SUP], Yashpal Singh Malik[SUP] 7 [/SUP]
Affiliations
- PMID: 33270497
- DOI: 10.1080/21645515.2020.1842683
Abstract
The rapid worldwide spread of the COVID-19 pandemic, caused by the newly emerged severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has resulted in tens of millions of infections and over one million deaths. SARS-CoV-2 infection affects all age groups; however, those over 60 years old are affected more severely. Moreover, pre-existing co-morbidities result in higher COVID-19-associated mortality in the geriatric population. This article highlights the associated risk factors of SARS-CoV-2 infection in older people and progress in developing COVID-19 vaccines, especially for efficient vaccination of the older population. There is also a summary of immunomodulatory and immunotherapeutic approaches to ameliorate the outcome of COVID-19 in older individuals.
Keywords: SARS-CoV-2; covid-19; elderly people; vaccine.